CD8A and neoplasm: There was also a significant difference in the number of patients with Okuda tumour stage I vs those with stage II or III in CD4 T-cell responders (χ2, P=0.04; 95% confidence intervals), whereas there was no difference in the number of patients with Okuda tumour stage I vs stage II or III in CD8 or total T-cell responders.